| Name | Title | Contact Details |
|---|
Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company`s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals.
We are T-Bird Pharma Inc., a public company listed on the TSX-V. We are the parent company to Thunderbird Biomedical Inc. Thunderbird is a licensed medical marijuana producer operating within the parameters of Health Canada`s MMPR. Thunderbird obtained a medical marijuana license to undertake the production of medical marijuana in February 2014, being the fifth company in Canada to obtain such a license. T-Bird is the publicly traded parent company of Thunderbird.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines. Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put science at the centre of everything we do. Science defines who we are. It is why we come to work every day and is part of our DNA. But this is only half of the story. We know that we do not have all the answers. We want to share ideas because we believe it results in better medicines. We want the way we work to be inclusive, open and collaborative. This approach runs through all that we do. We focus on three main therapy areas – Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory – and we are also selectively active in the areas of autoimmunity, neuroscience and infection. To put ourselves in the best position to push the boundaries of science, we seek to leverage our combination of capabilities, which encompass both small molecules and biologics, and include immunotherapies and developing innovative delivery devices that can offer choice to patients. These are reinforced by a strong focus on personalised healthcare capabilities, which aim to match medicines only to those patients who will benefit from them. Our teams also work alongside the world`s leading academic and biotech research institutions to stimulate innovation and evaluate emerging technologies such as Modified RNA and CRISPR genome editing. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Veranex transforms your MedTech innovation with solutions for medical device, diagnostic, precision medicine, digital health, and drug delivery technologies.